Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

International drug study shows rapid improvement in overactive bladder symptoms

09.10.2008
Patients with overactive bladders who took part in a multi-centre study to measure the effectiveness of solifenacin noticed improvements in as little as three days, according to research published in the November issue of BJU International.

Just over a hundred urology centres from 14 countries took part in the study of 863 patients led by Professor Linda Cardozo from the Department of Urogynaecology at King’s College Hospital in London.

During the 16-week double-blind randomised study, neither the researchers nor the patients were aware of which were taking solifenacin and which were taking the placebo or dummy drug. Three times as many patients took the active drug as the placebo.

The aim of the study was to see what effect the drug had on overactive bladder problems, in which patients feel an urgent need to pass urine and some can become incontinent. A number of novel and subjective outcome measures were used to assess urgency.

“This is the first study to assess urgency as the primary endpoint using the Patient Perception of Intensity and Urgency Scale (PPIUS), which ranges from zero to four with grades three and four representing urgency and urgency incontinence” explains Professor Cardozo.

“We also used the six-point Patients Perception of Bladder Condition score, visual analogue scales and patient diaries.”

Researchers found that on average patients taking solifenacin reported a 70 per cent reduction in severe urgency and urgency with incontinence, as measured by the PPIUS, compared with 50 per cent for those taking the placebo.

There were also statistically significant improvements when it came to all levels of urgency, maximum urgency intensity and urgency bother.

The clinicians taking part in the study reported that they recorded significant improvements in the patients taking solifenacin when they attended their one-week clinic visit after starting to take the drug.

“Solifenacin was significantly more effective than the placebo as early as day three” says Professor Cardozo. “Patients reported that they passed urine less frequently and also reported significant reductions in the number of daily incontinence and urgency incontinence episodes.

“Less than four per cent of the patients reported mild or moderately severe side effects when they took 5mg or 10mg doses of the drug and just 3.6 per cent of the solifenacin group stopped taking the drug.

“Looking at the solifenacin study group as a whole, just under 16 per cent reported dry mouth problems and seven per cent reported constipation.

“Just over two per cent of patients on the placebo also reported side effects. Three per cent reported dry mouth problems and two per cent reported constipation.

“It is common to notice a quite strong placebo effect in overactive bladder trials and this study is no exception. However, even a relatively small difference between active treatment and placebo outcomes might have a large influence on quality of life and treatment success.”

The study was carried out in two eight-week segments. In the first eight weeks 640 patients (74 per cent) were given 5mg daily of solifenacin and the remaining 223 received the placebo.

At the end of eight weeks, 46.5 per cent of patients receiving solifenacin requested a dose increase as did 66 per cent of the patients receiving the placebo.

Half of the solifenacin patients had their dose doubled from 5mg to 10mg and the other half were left on 5mg. The results from this secondary analysis will be published at a later date.

Approximately nine out of ten study participants were female and their average age was 58. Most had suffered from an overactive bladder for three to four years.

Patients were selected if they had suffered from an overactive bladder for more than three months and had had three or more urgency episodes, with or without incontinence, in the last three days. They had to be willing and able to keep a diary on when they emptied their bladder and the level of urgency and degree of bother they experienced.

“The rapid improvement that patients taking solifenacin reported is very important as patient expectations are high when they experience this highly distressing condition and they can become easily disillusioned if they don’t see early results” says Professor Cardozo, who wrote the international paper with experts from Germany, Italy, Spain, Belgium and The Netherlands.

“Our study found that solifenacin was consistently effective at reducing urgency and other symptoms associated with an overactive bladder and that simple scoring scales, such as the PPIUS, are a reliable way of measuring treatment outcome.”

Solifenacin is an oral antimuscarinic that was first marketed in 2004 and is now licensed for use in over 40 countries worldwide.

The SUNRISE study - the name is an acronym of the full study title - comprised 105 urology centres from 14 countries: Belgium, Czech Republic, Egypt, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Russia, Slovakia, Spain and the UK.

Annette Whibley | alfa
Further information:
http://www.bjui.org
http://interscience.wiley

More articles from Life Sciences:

nachricht Making fuel out of thick air
08.12.2017 | DOE/Argonne National Laboratory

nachricht ‘Spying’ on the hidden geometry of complex networks through machine intelligence
08.12.2017 | Technische Universität Dresden

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Midwife and signpost for photons

11.12.2017 | Physics and Astronomy

How do megacities impact coastal seas? Searching for evidence in Chinese marginal seas

11.12.2017 | Earth Sciences

PhoxTroT: Optical Interconnect Technologies Revolutionized Data Centers and HPC Systems

11.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>